Xavier Charest‐Morin

Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells

Sébastien Fortin, Xavier Charest‐Morin, Vanessa Turcotte et al. · Journal of Medicinal Chemistry · 2017 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models

Alexandre Parks, Xavier Charest‐Morin, Michael Boivin-Welch et al. · PeerJ · 2015 · 23 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

Green fluorescent protein fused to peptide agonists of two dissimilar G protein‐coupled receptors: novel ligands of the bradykinin B₂ (rhodopsin family) receptor and parathyroid hormone <scp>PTH</scp>₁ (secretin family) receptor

Xavier Charest‐Morin, Jean‐Philippe Fortin, Marie‐Thérèse Bawolak et al. · Pharmacology Research & Perspectives · 2013 · 19 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Pharmacological effects of recombinant human tissue kallikrein on bradykinin B₂receptors

Xavier Charest‐Morin, Arvind Raghavan, Matthew L. Charles et al. · Pharmacology Research & Perspectives · 2015 · 17 citations · Full text

Medicine, Biochemistry, Pharmacology +10

Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency

Xavier Charest‐Morin, Jacques Hébert, Georges‐Étienne Rivard et al. · Frontiers in Immunology · 2018 · 17 citations · Full text

Medicine, Molecular Biology, Pharmacology +13